Cancer Research UK Launches Trial of Lilly Cancer Candidate

06:41 EDT 23 Aug 2017 | Genetic Engineering News

Cancer Research UK said it has launched a Phase I trial of an Eli Lilly cancer candidate, a cell division cycle 7 kinase (Cdc7) inhibitor designed to fight numerous solid-tumor cancers with mutations of the p53 gene. LY3143921 hydrate is being studied for safety and tolerability, as well as for optimal dosage, in the trial, being carried out by Cancer Research UK’s Centre for Drug Development (CDD). Through its Clinical Development Partnership program, Cancer Research UK is partnering with Lilly to advance the drug in early-stage clinical studies. In earlier mouse studies, LY3143921 hydrate showed promise by selectively inhibiting Cdc7, a protein that assists cells in reproduction. The Phase I trial will assess the Cdc7 inhibitor in patients with metastatic bowel cancer, squamous non-small cell lung cancer and high grade serous ovarian cancer, as well as in patients with squamous carcinoma of the esophagus, squamous carcinoma of ...

Original Article: Cancer Research UK Launches Trial of Lilly Cancer Candidate


More From BioPortfolio on "Cancer Research UK Launches Trial of Lilly Cancer Candidate"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...